WO2023225613A3 - Combination anti-epn1 and anti-pd-l1 antibody therapies - Google Patents

Combination anti-epn1 and anti-pd-l1 antibody therapies Download PDF

Info

Publication number
WO2023225613A3
WO2023225613A3 PCT/US2023/067195 US2023067195W WO2023225613A3 WO 2023225613 A3 WO2023225613 A3 WO 2023225613A3 US 2023067195 W US2023067195 W US 2023067195W WO 2023225613 A3 WO2023225613 A3 WO 2023225613A3
Authority
WO
WIPO (PCT)
Prior art keywords
epn1
targeting
combination
antibody therapies
cell death
Prior art date
Application number
PCT/US2023/067195
Other languages
French (fr)
Other versions
WO2023225613A2 (en
Inventor
Matthew K. Robinson
Michael John MORIN
John P. Dowling
Fang Shen
Original Assignee
Immunome, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome, Inc. filed Critical Immunome, Inc.
Publication of WO2023225613A2 publication Critical patent/WO2023225613A2/en
Publication of WO2023225613A3 publication Critical patent/WO2023225613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to treating cancer by targeting the cell membrane-localized adaptor protein, Epsin-1 (EPN1), in combination with targeting one or more immune checkpoint proteins, including targeting programmed cell death-ligand 1 (PD-L1) and/or targeting Programmed cell death protein 1 (PD-1)
PCT/US2023/067195 2022-05-18 2023-05-18 Combination anti-epn1 and anti-pd-l1 antibody therapies WO2023225613A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263343282P 2022-05-18 2022-05-18
US63/343,282 2022-05-18
US202263368583P 2022-07-15 2022-07-15
US63/368,583 2022-07-15
US202263380457P 2022-10-21 2022-10-21
US63/380,457 2022-10-21

Publications (2)

Publication Number Publication Date
WO2023225613A2 WO2023225613A2 (en) 2023-11-23
WO2023225613A3 true WO2023225613A3 (en) 2023-12-28

Family

ID=88836167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/067195 WO2023225613A2 (en) 2022-05-18 2023-05-18 Combination anti-epn1 and anti-pd-l1 antibody therapies

Country Status (1)

Country Link
WO (1) WO2023225613A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
US20210347895A1 (en) * 2018-10-17 2021-11-11 Immunome, Inc. Exosome-targeting bispecific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
US20210347895A1 (en) * 2018-10-17 2021-11-11 Immunome, Inc. Exosome-targeting bispecific antibodies

Also Published As

Publication number Publication date
WO2023225613A2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
EA202091976A1 (en) VARIABLE ANTIBODY DOMAINS TARGETING CD33 AND THEIR APPLICATION
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX2021005236A (en) Dosing regimen of anti-tigit antibody for treatment of cancer.
CO2022008314A2 (en) Anti-mertk antibodies and methods of using them
MX2020012613A (en) Compositions and uses thereof for treating disease or condition.
MX2022016192A (en) Conditionally active anti-nectin-4 antibodies.
BR112021018608A2 (en) Antibodies to claudin-6 and drug conjugates
WO2022082073A3 (en) Compositions and methods for muc18 targeting
BR112021016121A2 (en) Isolated antibody that binds to tumor tissue, antibody that binds to tumor tissue, method of inducing an immune response, method of treating a cancer patient with a tumor, method of identifying a patient that has a tumor, expression vector, cell host, method of producing an antibody, method of identifying an antibody with antitumor activity, use of an antibody and polypeptide
MX2020002301A (en) Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer.
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
BR112021017703A8 (en) HIGH AVIDITY WT1 T CELL RECEPTORS AND USES THEREOF
BR112023002150A2 (en) ANTIBODIES TARGETING EGFR AND THEIR USE
WO2023225613A3 (en) Combination anti-epn1 and anti-pd-l1 antibody therapies
WO2021226163A3 (en) Antibodies targeting clec12a and use thereof
PT1292289E (en) Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
MX2024001214A (en) Methods and compositions for treating cancer.
MX2022003610A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
WO2020212756A3 (en) Reprogramming of polymorphonuclear leukocytes
MX2021008453A (en) Formulations of antibodies that bind human cd137 and uses thereof.
BR112021020163A2 (en) Antibodies against programmed death ligand 1 and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23808587

Country of ref document: EP

Kind code of ref document: A2